フォロー
Kai Rejeski
Kai Rejeski
確認したメール アドレス: med.uni-muenchen.de
タイトル
引用先
引用先
CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma
K Rejeski, A Perez, P Sesques, E Hoster, C Berger, L Jentzsch, ...
Blood, The Journal of the American Society of Hematology 138 (24), 2499-2513, 2021
2512021
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals
N Philipp, M Kazerani, A Nicholls, B Vick, J Wulf, T Straub, M Scheurer, ...
Blood, The Journal of the American Society of Hematology 140 (10), 1104-1118, 2022
992022
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
K Rejeski, A Perez, G Iacoboni, O Penack, V Bücklein, L Jentzsch, ...
Journal for immunotherapy of cancer 10 (5), 2022
842022
SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells
Y Liang, T Tebaldi, K Rejeski, P Joshi, G Stefani, A Taylor, Y Song, ...
Leukemia 32 (12), 2659-2671, 2018
762018
Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
K Rejeski, M Subklewe, M Aljurf, E Bachy, A Balduzzi, P Barba, B Bruno, ...
Blood 142 (10), 865-877, 2023
742023
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
G Iacoboni, K Rejeski, G Villacampa, JA van Doesum, A Chiappella, ...
Blood advances 6 (12), 3606-3610, 2022
622022
Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell …
K Rejeski, WG Kunz, M Rudelius, V Bücklein, V Blumenberg, C Schmidt, ...
BMC infectious diseases 21, 1-8, 2021
442021
Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy
G Iacoboni, V Navarro, AÁ Martín-López, K Rejeski, M Kwon, KA Jalowiec, ...
Journal of Clinical Oncology 42 (2), 205-217, 2024
422024
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
K Rejeski, A Burchert, G Iacoboni, P Sesques, L Fransecky, V Bücklein, ...
Blood advances 6 (16), 4719-4725, 2022
412022
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
K Rejeski, DK Hansen, R Bansal, P Sesques, S Ailawadhi, JM Logue, ...
Journal of Hematology & Oncology 16 (1), 88, 2023
342023
AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms
K Rejeski, J Duque-Afonso, M Lübbert
Oncogene 40 (38), 5665-5676, 2021
312021
Toxicities and response rates of secondary CNS lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T cells
P Karschnia, K Rejeski, M Winkelmann, F Schöberl, VL Bücklein, ...
Neurology 98 (21), 884-889, 2022
302022
Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL
K Rejeski, Z Wu, V Blumenberg, WG Kunz, S Müller, S Kajigaya, S Gao, ...
Blood, The Journal of the American Society of Hematology 140 (20), 2175-2179, 2022
262022
An international survey on grading, diagnosis, and management of immune effector cell-associated hematotoxicity (ICAHT) following CAR T-cell therapy on behalf of the EBMT and EHA
K Rejeski, R Greco, F Onida, I Sánchez-Ortega, C Bonini, A Sureda, ...
Hemasphere 7 (5), e889, 2023
252023
Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B …
DMC Dos Santos, K Rejeski, M Winkelmann, L Liu, P Trinkner, S Günther, ...
Haematologica 107 (9), 2096, 2022
252022
Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies
E Kampouri, JS Little, K Rejeski, O Manuel, SP Hammond, JA Hill
Transplant Infectious Disease 25, e14157, 2023
212023
Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells
P Karschnia, KC Miller, AJ Yee, K Rejeski, PC Johnson, N Raje, ...
Blood 142 (14), 1243-1248, 2023
212023
Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment
F Schoeberl, S Tiedt, A Schmitt, V Blumenberg, P Karschnia, VG Burbano, ...
Blood advances 6 (10), 3022-3026, 2022
212022
Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma
K Rejeski, MD Jain, EL Smith
Transplantation and Cellular Therapy 29 (7), 418-428, 2023
172023
Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy
M Winkelmann, V Blumenberg, K Rejeski, VL Bücklein, M Ruzicka, ...
European journal of nuclear medicine and molecular imaging 50 (5), 1406-1413, 2023
172023
現在システムで処理を実行できません。しばらくしてからもう一度お試しください。
論文 1–20